Literature DB >> 25282593

Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed.

Stefano Fedele1, Giorgio Bedogni2, Matteo Scoletta3, Gianfranco Favia4, Giuseppe Colella5, Alessandro Agrillo6, Giordana Bettini7, Olga Di Fede8, Giacomo Oteri9, Vittorio Fusco10, Mario Gabriele11, Livia Ottolenghi12, Stefano Valsecchi13, Stephen Porter14, Polly Pok-Lam Fung14, Giorgia Saia7, Giuseppina Campisi8, Alberto Bedogni15.   

Abstract

Recent data suggest that the traditional definition of bisphosphonate-associated osteonecrosis of the jaw (ONJ) may exclude patients who present with the non-exposed variant of the condition. To test the hypothesis that a proportion of patients with ONJ remain undiagnosed because their symptoms do not conform to the traditional case definition, we did a secondary analysis of data from MISSION (Multicentre study on phenotype, definition and classification of osteonecrosis of the jaws associated with bisphosphonates), a cross-sectional study of a large population of patients with bisphosphonate-associated ONJ who were recruited in 13 European centres. Patients with exposed and non-exposed ONJ were included. The main aim was to quantify the proportion of those who, according to the traditional case definition, would not be diagnosed with ONJ because they had no exposed necrotic bone. Data analysis included descriptive statistics, median regression, and Fisher's exact test. A total of 886 consecutive patients were recruited and 799 were studied after data cleaning (removal or correction of inaccurate data). Of these, 607 (76%) were diagnosed according to the traditional definition. Diagnosis in the remaining 192 (24%) could not be adjudicated, as they had several abnormal features relating to the jaws but no visible necrotic bone. The groups were similar for most of the phenotypic variables tested. To our knowledge this is the first study in a large population that shows that use of the traditional definition may result in one quarter of patients remaining undiagnosed. Those not considered to have ONJ had the non-exposed variant. These findings show the importance of adding this description to the traditional case definition.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Bisphosphonates; Jawbones; Osteonecrosis

Mesh:

Substances:

Year:  2014        PMID: 25282593     DOI: 10.1016/j.bjoms.2014.09.001

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  28 in total

Review 1.  Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity.

Authors:  Valesca Sander Koth; Maria Antonia Figueiredo; Fernanda Gonçalves Salum; Karen Cherubini
Journal:  Dentomaxillofac Radiol       Date:  2016-05-31       Impact factor: 2.419

2.  Interrelationship of clinical, radiographic and haematological features in patients under bisphosphonate therapy.

Authors:  Valesca S Koth; Maria A Figueiredo; Fernanda G Salum; Karen Cherubini
Journal:  Dentomaxillofac Radiol       Date:  2017-02-17       Impact factor: 2.419

3.  Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy-histomorphometric and immunohistochemical analysis.

Authors:  Miguel Luciano Silva; Leandro Tasso; Alan Arrieira Azambuja; Maria Antonia Figueiredo; Fernanda Gonçalves Salum; Vinicius Duval da Silva; Karen Cherubini
Journal:  Clin Oral Investig       Date:  2016-03-09       Impact factor: 3.573

4.  Treatment of Medication-Related Osteonecrosis of the Jaw and its Impact on a Patient's Quality of Life: A Single-Center, 10-Year Experience from Southern Italy.

Authors:  Giacomo Oteri; Gianluca Trifirò; Matteo Peditto; Loredana Lo Presti; Ilaria Marcianò; Francesco Giorgianni; Janet Sultana; Antonia Marcianò
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

Review 5.  Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.

Authors:  Athanasios D Anastasilakis; Jessica Pepe; Nicola Napoli; Andrea Palermo; Christos Magopoulos; Aliya A Khan; M Carola Zillikens; Jean-Jacques Body
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

6.  Dental Implant Supported Restorations Improve Quality of Life in Osteoporotic Women.

Authors:  Christine DeBaz; Jenna Hahn; Lisa Lang; Leena Palomo
Journal:  Int J Dent       Date:  2015-06-03

7.  Existing data sources for clinical epidemiology: Scandinavian Cohort for osteonecrosis of the jaw - work in progress and challenges.

Authors:  Morten Schiodt; Cecilia Larsson Wexell; Bente Brokstad Herlofson; Karen Marie Giltvedt; Sven Erik Norholt; Vera Ehrenstein
Journal:  Clin Epidemiol       Date:  2015-01-30       Impact factor: 4.790

8.  Current controversies in classification, management, and prevention of bisphosphonate-related osteonecrosis of the jaw.

Authors:  Giuliano Ascani; Giuseppina Campisi; Luis Manuel Junquera Gutierrez
Journal:  Int J Dent       Date:  2014-12-21

9.  Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases.

Authors:  Francesco Erovigni; Alessio Gambino; Marco Cabras; Antonella Fasciolo; Silvio Diego Bianchi; Elisa Bellini; Vittorio Fusco
Journal:  Dent J (Basel)       Date:  2016-10-29

Review 10.  Medication-related osteonecrosis of the jaw: Clinical and practical guidelines.

Authors:  Daniele Rosella; Piero Papi; Rita Giardino; Emauele Cicalini; Luca Piccoli; Giorgio Pompa
Journal:  J Int Soc Prev Community Dent       Date:  2016 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.